The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Alejandro Fuchs - Itau Corretora de Valores S.A. - Analyst
: Thank you. Olß, Marco, Antonio, Christianne and team. Congratulations on the super strong results and thank you for the space for questions. I
have two quick ones on my side. The first one regarding Suerox, the product continues to see material growth and demand. I wanted to know if
you can share with us a little bit your thoughts about Suerox outside of Mexico. How do you see the positioning of the product, the growth prospects
for the future, especially in the US and in that time, I know that you said that in the US, it's growing strongly, but maybe you can share with a little
bit about the strategy going forward.
And then the second is on Argentina, also very strong results despite the macro headwinds. So I was wondering if you can maybe share with us
how do you see the business developing in Argentina towards next year? Thank you.
Question: Alejandro Fuchs - Itau Corretora de Valores S.A. - Analyst
: Yes, it was very clear. (inaudible) Marco.
Question: Luis Pardo - Compass Group, L.L.C. - Analyst
: Great. Do you guys hear me?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
OCTOBER 24, 2024 / 5:00PM, LABB.MX - Q3 2024 Genomma Lab Internacional SAB de CV Earnings Call
Question: Luis Pardo - Compass Group, L.L.C. - Analyst
: Okay, great. First of all, congrats once again, outpacing even the most optimistic of estimates. So thanks and great, great job, Tony and Marco.
The question I have is more because if I look at how you're driving this productivity initiatives, until when should we expect continued sequential
improvements in margins? Should we continue to see it for all of 2025, maybe 2026? I know you don't like to give long term guidance but help me
modeling -- help me with the model because it's hard to keep up the pace with you guys. You're always beating my numbers.
Question: Luis Pardo - Compass Group, L.L.C. - Analyst
: Perfect. And just one quick follow up. You're generating a ton of cash. Could you remind us of your priorities for capital allocation?
Question: Luis Pardo - Compass Group, L.L.C. - Analyst
: Olß, Antonio, (inaudible)
Question: Luis Pardo - Compass Group, L.L.C. - Analyst
: Thank you.
Question: Luis Pardo - Compass Group, L.L.C. - Analyst
: Great, super clear. Thank you, guys, and congrats again.
Question: Antonio Hernandez - Actinver - Analyst
: Hi. Good morning. Thanks for taking my question and congrats on the very solid results.
Could you provide a little bit more light on the recent isotonics acquisitions that you made and this type of bolt-on acquisitions? Like maybe if
there's any specific category or region where you're -- that you're targeting?
Question: Andres Radin - Rohatyn Group - Analyst
: Hi, guys. Congratulations on another solid quarter.
Two questions on my end. The first one is we saw a very good performance in the US, even when taking into account the FX. Maybe you can give
us some color, what kind of strategies you are implementing there and what can we expect for the next year? In terms of additional benefits can
we expect from the approval of the GMP permits in Mexico?
Question: Andres Radin - Rohatyn Group - Analyst
: Yeah, great. Thank you.
Question: Andres Radin - Rohatyn Group - Analyst
: Great. Thank you. And again, congratulations.
Question: Jorge Izquierdo - BTG Pactual - Analyst
: Hey, Marco and Antonio, hope you are well and congrats on the results. As you show in the presentation, haircare, blades and skincare categories
are underperforming the rest of the portfolio. So I was wondering if you could share more details on what is affecting each of these categories,
please. Thank you and congrats, again.
Question: Jorge Izquierdo - BTG Pactual - Analyst
: Great. Very clear. Thank you.
Question: Martin Zetzsche - Fundamenta Investments - Analyst
: Hello. Yeah. Sorry. I was muted on the microphone but not -- didn't click the call. Sorry. Hi, Marco, Antonio. And thanks for taking the question. I
have two. My first question is regarding the other current liabilities. We saw a MXN700 million increase on that line. My question is basically what's
the effect there and what explains it? And the second one is regarding the other acquisitions line. The almost MXN600 million we see in the cash
flow statement, are those payments made for the purchases of brands made in Argentina or what's there?
| 
